adagrasib + pemetrexed + pembrolizumab

Adagrasib + pemetrexed + pembrolizumab is an experimental combination regimen under clinical investigation for the first-line treatment of advanced or metastatic non–small cell lung cancer (NSCLC) with KRAS G12C mutation. **Adagrasib** is a small molecule inhibitor specifically targeting KRAS G12C, a mutant form of the KRAS protein seen in some lung cancers. **Pemetrexed** is a folate antimetabolite chemotherapy that disrupts folate-dependent processes essential for cell replication. **Pembrolizumab** is a monoclonal antibody acting as an immune checkpoint inhibitor, blocking programmed cell death protein 1 (PD-1) to enhance anti-tumor immune response. The combination is designed to concurrently inhibit cancer-driving mutations at the molecular level, block DNA synthesis in cancer cells, and activate immune-mediated tumor cell killing. Recent and ongoing Phase 2 and Phase 3 clinical trials are assessing safety and efficacy, particularly in patients with high PD-L1 expression. This combination has shown promising activity and a manageable safety profile in early-phase trials for NSCLC with KRAS G12C mutation[1][4][7][9].